Chromocell Therapeutics Corp. (AMEX:CHRO)’s traded shares stood at 0.75 million during the last session. At the last check today, the stock’s price was $0.70, to imply an increase of 4.16% or $0.03 in intraday trading. The CHRO share’s 52-week high remains $6.00, putting it -757.14% down since that peak but still an impressive 25.71% since price per share fell to its 52-week low of $0.52. The company has a valuation of $4.04M, with an average of 0.32 million shares in intraday trading volume over the past 10 days and average of 111.08K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Chromocell Therapeutics Corp. (CHRO), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CHRO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.55.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Chromocell Therapeutics Corp. (AMEX:CHRO) trade information
After registering a 4.16% upside in the latest session, Chromocell Therapeutics Corp. (CHRO) has traded red over the past five days. The 5-day price performance for the stock is -9.04%, and -6.82% over 30 days. With these gigs, the year-to-date price performance is -85.42%. Short interest in Chromocell Therapeutics Corp. (AMEX:CHRO) saw shorts transact 31672.0 shares and set a 0.24 days time to cover.
CHRO Dividends
Chromocell Therapeutics Corp. has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Chromocell Therapeutics Corp. (AMEX:CHRO)’s Major holders
Going by data provided on Aug 31, 2024, Fidelity Extended Market Index Fund holds roughly 5.01 shares. This is just over 0.09% of the total shares, with a market valuation of $3531.0
